Bone loss in the oestrogen-depleted rat is not exacerbated by sitagliptin, either alone or in combination with a thiazolidinedione.
about
Vildagliptin has the same safety profile as a sulfonylurea on bone metabolism and bone mineral density in post-menopausal women with type 2 diabetes: a randomized controlled trial.Diabetes medications and bone.Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review.Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.Diabetes Drug Effects on the Skeleton.Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms.
P2860
Bone loss in the oestrogen-depleted rat is not exacerbated by sitagliptin, either alone or in combination with a thiazolidinedione.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Bone loss in the oestrogen-dep ...... tion with a thiazolidinedione.
@en
Bone loss in the oestrogen-dep ...... tion with a thiazolidinedione.
@nl
type
label
Bone loss in the oestrogen-dep ...... tion with a thiazolidinedione.
@en
Bone loss in the oestrogen-dep ...... tion with a thiazolidinedione.
@nl
prefLabel
Bone loss in the oestrogen-dep ...... tion with a thiazolidinedione.
@en
Bone loss in the oestrogen-dep ...... tion with a thiazolidinedione.
@nl
P2093
P2860
P356
P1476
Bone loss in the oestrogen-dep ...... ation with a thiazolidinedione
@en
P2093
B L Pennypacker
D B Kimmel
H Glantschnig
J E Fisher
R B Langdon
P2860
P304
P356
10.1111/DOM.12109
P50
P577
2013-05-01T00:00:00Z